Introduction
The incidence of venous thromboembolic (VTE) events in children has increased in recent years, perhaps because of increased use of central venous catheters (CVCs) and the survival of children with previously fatal conditions [1] [2] [3] . However, VTE is still comparatively rare in children with frequencies estimated to be one tenth to one hundredth of that in the adult population 1, 2 . Nevertheless, it is an important cause of potentially preventable mortality and morbidity in children.
The Canadian VTE Registry, which is the largest published, comprises prospectively collected data from 15 tertiary care centres. In a report from this registry analysing 405 consecutive cases of VTE in children aged one month to 18 years over a six year period, the mortality attributed to thromboses was 2.2% 3 . Unlike adults, children often survive for sixty years or more following VTE, and post-thrombotic syndrome (PTS), a condition marked by limb swelling and pain aggravated by activity, may develop in 50% of children who have experienced VTE 4 .
Current clinical guidelines issued by the National Institute for Health and Clinical
Excellence (NICE) in January 2010 for reducing the risk of venous thromboembolism apply only to patients over the age of 18 years 5 . In view of the potential mortality, morbidity, increased length of hospital stay and associated increased health costs of VTE in children, the case for similar guidelines for the paediatric population particularly in the critical care setting, (paediatric intensive care and high dependency services), is compelling.
However, given the rarity of paediatric VTE, the risk-to-benefit ratio for formal prophylaxis remains controversial. For more than 10 years there have been calls 21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  P  e  e  r  R  e  v  i  e  w for prospective randomised trials to define an effective strategy for preventing deep vein thrombosis (DVT) in children judged to be at risk 3 . To date such trials have not materialised.
The aims of this paper were to audit the current practice in paediatric VTE prophylaxis in critical care units across England and Wales, to promote daily VTE risk review and propose simple preventative measures. We illustrate the importance of the condition with a series of patients who developed DVT over the course of 24 months at the South West Paediatric Burns and Neurosurgical Services based in Bristol. Audit Network' website 6 and every centre admitting critically ill children with burns in England and Wales was contacted by telephone. A single senior member RIJ catheter that had been in place for five days. After receiving a heparin infusion for 6 days, she was given low molecular weight heparin (LMWH). Given the large surface area of her burns, tinzaparin was used to minimize the number of injections. After a 72 day hospitalization she was discharged home on LMWH for 3 months. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Only one of the 24 units surveyed had written guidelines designed specifically for the prevention of VTE in children. Two units used adult guidelines in adolescent patients aged over 12 years based on those issued by NICE. A fourth unit admitting children with burns used adult guidelines for children 13 years and over and modified guidelines for children under 13 years. A fifth unit had hospital-wide guidelines for patients, including children, admitted with diabetic ketoacidosis (DKA), which included LMWH prophylaxis.
In units with no written guidelines, individual case-based decisions regarding VTE prophylaxis were ad hoc and usually consultant-led. Risk of VTE was 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r P e e r R e v i e w inserted central catheters are also associated with the development of VTE although the incidence is lower (up to 9%) than when the catheter is inserted centrally 10 . Younger and smaller children are more likely to develop catheterrelated VTE 11 which suggests that vessel size may be important. In the upper venous system the risk of VTE is increased significantly with a CVC in the subclavian veins, suggesting that placement in the brachial or jugular veins may be preferable 12 . Young children with diabetic ketoacidosis have an increased incidence of clinical DVT associated with the placement of CVCs which may be related to dehydration 13 . . The literature therefore reflects that CVCs are a major risk factor for childhood VTE particularly in those children that are less than one year of age, those admitted following trauma or with underlying malignancy. It is therefore important that CVCs should be removed as soon as possible and a simple risk benefit analysis should be undertaken at least daily 14 .
Despite the documented increase in the incidence of paediatric VTE and calls for the effects of prophylactic measures to be studied, our survey confirms that in England and Wales only one PICU uses written guidelines devised specifically for children and there is wide variation in clinical practice. Awareness of the risk of VTE within units also appears to vary enormously, some units addressing such risk daily and others not. When non-pharmaceutical measures were taken, the age and patient groups deemed at risk varied between units.
In contrast to VTE prevention in adults, the options for non-pharmaceutical prophylactic measures for smaller children are limited: TEDs are only available for a calf circumference greater than 25cm and a toe to knee measurement 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 patients HB CVCs were shown to reduce the incidence of CVC related thrombosis significantly 15 , although there seems to be no advantage in using HB CVCs in infants less than one year old 16 . The use of LMWH for primary prophylaxis in children must not be undertaken lightly. In a review of the literature since 1980, LMWHs were found to be associated with minor bleeding in 21% and major bleeding in 3% of patients receiving primary prophylaxis 17 . There is one previously published paediatric VTE guideline 18 .
We propose the following based on our survey, case review within our regional childrens services and a formal literature review; that all paediatric critical care areas formally assess risk of VTE daily, that CVCs are removed as soon as possible particularly in children less than one year of age and that non-pharmacological prophylactic measures are used where appropriate and feasible. LMWHs should be used only in high-risk patients and at the discretion of the consultants responsible.
In our unit we have implemented a risk assessment table similar to that used in our adult population according to the new adult NICE guidelines 5
( Figure 1) . Five of the six cases seen at our hospital occurred in association with a CVC and all six had a combination of other risk factors. In most instances the CVC could have been removed earlier, the patients identified as medium to high risk for the development of VTE, and additional 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 This paper aims to raise the profile of VTE prevention in children. To devise a protocol which would be applicable across all areas and ages is difficult but we encourage units to develop their own guidelines in collaboration with the specialties involved.
Summary
VTE is a recognised cause of preventable mortality and morbidity in children and with the increasing use of CVCs the incidence of VTE is rising. Our case series highlights the problem in a typical cohort of critically ill children following neurosurgery, trauma and major burn injuries. The survey confirms that there is no consensus in the England and Wales as to which prophylactic measures against VTE should be applied in patients of less than 18 years of age. Given the rarity of VTE events in children it is unlikely that randomised controlled trials will clarify this. We therefore propose that a risk assessment 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 If child has a short term CVC present, the line should be removed within 24 hours unless a consultant documents that it should remain in situ. CVC in an infant is a very high risk.
Interventions may include:
• Adequate hydration • Early mobilization if possible • TEDs/ Flowtrons if available for size of child.
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